NEWS IN BRIEF
Ardena: M&A growth fuels HQ expansion
According to the contract development and manufacturing organisation (CDMO), a sustained period of growth, driven by mergers and acquisitions, prompted the move.
“After several acquisitions and an ongoing growth period, we are firmly on track to reach our €35m ($39.7m) sales target for 2018 as part of our wider strategy to become a leading integrated drug development company,” said CEO Harry Christiaens.
Ardena was formed in 2017, as the result of a merger between Pharmavize, Crystallics and Analytical Biochemical Laboratory (ABL).
The CDMO has since integrated active pharmaceutical ingredient (API) and nanomedicine maker, ChemConnection, as well as API and excipient-focused Syntagon into its business.
Christiaens continued: “This new, larger headquarters will enable us to free up space for additional laboratories at our other sites and further expand our capabilities.
“It will also provide a base for our staff training centre to ensure we develop our team.”
